| Population 2012
|
47 million
|
| |
| | |
| Estimates of TB burden * 2012
|
Number (thousands)
|
Rate
(per 100 000 population)
|
| Mortality (excludes HIV+TB)
|
0.27
|
(0.26–0.27)
|
0.57
|
(0.57–0.58)
|
| Mortality (HIV+TB only)
|
0.066
|
(0.05–0.095)
|
0.14
|
(0.11–0.2)
|
| Prevalence (includes HIV+TB)
|
8.1
|
(3.2–15)
|
17
|
(6.8–33)
|
| Incidence (includes HIV+TB)
|
6.5
|
(5.7–7.4)
|
14
|
(12–16)
|
| Incidence (HIV+TB only)
|
0.58
|
(0.51–0.66)
|
1.3
|
(1.1–1.4)
|
| Case detection, all forms (%)
|
87
|
(77–99)
|
|
|
| |
| | |
| TB case notifications 2012
|
|
|
|
|
| New cases
|
|
(%)
|
Retreatment cases
|
(%)
|
| Smear-positive
|
1 984
|
(37)
|
Relapse
|
0
|
(0)
|
| Smear-negative
|
1 595
|
(30)
|
Treatment after failure
|
0
|
(0)
|
| Smear-unknown / not done
|
260
|
(5)
|
Treatment after default
|
0
|
(0)
|
| Extrapulmonary
|
1 508
|
(28)
|
Other
|
314
|
(100)
|
| Other
|
0
|
(0)
|
|
|
|
| Total new
|
5 347
|
|
Total retreatment
|
314
|
|
|
|
|
|
|
|
|
| Other (history unknown)
|
330
|
|
|
|
|
| Total new and relapse
|
5 347
|
|
Total cases notified
|
5 991
|
|
| |
| | |
| New cases
|
Smear-positive
|
Smear-negative/ unknown/
not done
|
Extrapulmonary
|
| M:F ratio
|
2.1
|
1.7
|
1.2
|
| Age < 15
|
25
|
245
|
73
|
| | |
| | |
| Laboratories
|
2012
|
| Is second-line drug susceptibility testing available?
|
Yes, in country
|
| |
| | |
| Treatment success rate 2011 (%)
|
|
|
|
|
| New smear-positive and/or culture-positive
|
73
|
|
Is rifampicin used
throughout treatment for
new patients?
|
Yes
|
| New smear-negative/extrapulmonary
|
70
|
|
| Retreatment
|
56
|
|
| |
| | |
| TB/HIV 2012
|
Number
|
(%)
|
| TB patients with known HIV status
|
4 179
|
(70)
|
| HIV-positive TB patients
|
370
|
(9)
|
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
|
|
|
| HIV-positive TB patients on antiretroviral therapy (ART)
|
|
|
| HIV-positive people screened for TB
|
|
|
| HIV-positive people provided with IPT
|
|
|
| | |
| | |
| Estimates of MDR-TB burden 2012*
|
|
New
|
|
Retreatment
|
| % of TB cases with MDR-TB
|
0.22
|
(0.03–0.8)
|
7.1
|
(3.3–13)
|
MDR-TB cases among notified pulmonary
TB cases
|
9
|
(1–31)
|
22
|
(10–41)
|
| |
| | |
| Reported cases of MDR-TB 2012
|
New
|
Retreatment
|
Total
|
| Cases tested for MDR-TB
|
802 (21%)
|
69 (22%)
|
871
|
| Laboratory-confirmed MDR-TB cases
|
26
|
11
|
37
|
| Patients started on MDR-TB treatment
|
|
|
|
| |
| | |
| Financing TB control
|
2013
|
| National TB programme budget (US$ millions)
|
|
| |
| | |